BMRN BioMarin Pharmaceutical Inc.

127.55
+0.77  (+1%)
Previous Close 126.78
Open 127.77
52 Week Low 62.88
52 Week High 128.77
Market Cap $23,065,740,983
Shares 180,836,856
Float 158,015,040
Enterprise Value $22,931,178,603
Volume 656,332
Av. Daily Volume 1,692,949
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
Cerliponase alfa
Batten Disease
Approved
Approved
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.
Valoctocogene roxaparvovec (BMN 270)
Hemophilia A
PDUFA priority review
PDUFA priority review
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.
Vosoritide
Achondroplasia
NDA Filing
NDA Filing
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.
Valoctocogene roxaparvovec (BMN 270) - GENEr8-1
Hemophilia A
Phase 3
Phase 3
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.

Drug Pipeline

Drug Stage Notes
BMN 307
Phenylketonuria (PKU)
Phase 1/2
Phase 1/2
Phase 1/2 trial to commence dosing 2H 2020.
Valoctocogene roxaparvovec (BMN 270)
Hemophilia A with with pre-existing AAV5 antibodies
Phase 1/2
Phase 1/2
Phase 1/2 dosing has commenced - noted May 15, 2018.
Palynziq (Pegvaliase)
Phenylketonuria (PKU)
Approved
Approved
Approval announced May 24, 2018.
Kyndrisa
Duchenne Muscular Dystrophy (DMD)
CRL
CRL
CRL issued January 14, 2016.
Vimizim (GALNS)
(MPS IVA) Morquio A Syndrome
Approved
Approved
Approved February 14, 2014.

Latest News

  1. SAN RAFAEL, Calif., June 29, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced the promotions of Brian R. Mueller to Executive Vice President, Chief Financial Officer and of Andrea L. Acosta to Group Vice President, Chief Accounting Officer.  Mr. Mueller had been serving as Senior Vice President, Acting CFO since February this year.

    "After an exhaustive search of internal and external candidates, Brian was the most qualified as a 17-year veteran at BioMarin in finance combined with his demonstration of leadership as acting CFO.  I am confident that Brian's experience, skills, and commitment to the Company will be integral to our growth into profitability," said Jean-Jacques Bienaimé, Chairman and Chief Executive Officer at BioMarin.  "It also was clear that Andrea's leadership within our Finance organization and experience made her the most qualified candidate for Chief Accounting Officer to assume Brian's previous role.  It is a credit to BioMarin that we have such deep bench strength in our finance organization to be able to promote two highly qualified people into these key leadership roles as the company transitions into its next evolutionary phase of growth."

    "It is an honor to be selected for the CFO role at BioMarin.  I have been a part of the Company's growth over the last two decades, and I am looking forward to continuing to support our efforts to develop therapies that make a meaningful difference in small patient populations," said Brian R. Mueller, Executive Vice President, Chief Financial Officer.  "As the company continues to develop breakthrough therapies for rare disease patients, the Finance function is positioned as a strategic partner to our critical research and development, technical, and commercial operations."

    "I am looking forward to bringing my experience to the role of Chief Accounting Officer and to supporting the Company's strategic goals over the coming years," said Andrea L. Acosta, Group Vice President, Chief Accounting Officer.  "It is important that the crucial work that BioMarin is doing to advance the standard of care for rare disease patients is supported by a finance organization that is sensitive to the specific needs to fuel innovation."

    Mr. Mueller has been with BioMarin since December 2002, during which time he has taken on roles of increasing responsibility.  Prior to being Senior Vice President, Acting CFO, he served as Senior Vice President, Finance and Chief Accounting Officer and as Group Vice President, Corporate Controller.  Before joining BioMarin, Mr. Mueller worked for KPMG as a senior manager in the firm's audit practice. Mr. Mueller joined KPMG after Arthur Andersen LLP ceased operations in June 2002, prior to which he spent seven years with Arthur Andersen LLP in the firm's audit and business advisory services practice.  From June 2014 to May 2020, Mr. Mueller was a member of the board of directors of Anthera Pharmaceuticals, Inc., a previously public biopharmaceutical company, where he also served as Chairman of the Audit Committee. Mr. Mueller received a B.S. in Accountancy from Northern Illinois University in DeKalb, Illinois, and is a member of the American Institute of Certified Public Accountants.

    Ms. Acosta joined BioMarin in 2017 as Vice President, Corporate Controller.  Prior to BioMarin, Ms. Acosta worked at Levi Strauss & Co. as Vice President, Global Controller and Principal Accounting Officer where she had various roles of increasing responsibility in finance management during her tenure.  Previously, she worked at KPMG LLP as a manager in the firm's audit practice.  She earned a BS in Accounting at San Francisco State University and is a Certified Public Accountant. 

    About BioMarin

    BioMarin is a global biotechnology company that develops and commercializes innovative therapies for patients with serious and life-threatening rare and ultra-rare genetic diseases. The company's portfolio consists of six commercialized products and multiple clinical and pre-clinical product candidates. For additional information, please visit www.biomarin.com. Information on such website is not incorporated by reference into this press release.

    Forward-Looking Statement

    This press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc. (BioMarin), including, without limitation, statements about: Mr. Mueller's promotion and his anticipated contributions to the company's growth and profitability, Ms. Acosta's promotion, and the Company's ability to execute on its growth and profitability goals. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: Mr. Mueller continuing employment as anticipated, possible complications associated with the leadership transition within the Finance organization, and those factors detailed in BioMarin's filings with the Securities and Exchange Commission (SEC), including, without limitation, the factors contained under the caption "Risk Factors" in BioMarin's Quarterly Report on Form 10-Q for the quarter ended March 31, 2019 as such factors may be updated by any subsequent reports. Stockholders are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin is under no obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.

    BioMarin® is a registered trademark of BioMarin Pharmaceutical Inc.

    Contact:

    Investors: 

    Media:

    Traci McCarty 

    Debra Charlesworth

    BioMarin Pharmaceutical Inc. 

    BioMarin Pharmaceutical Inc.

    (415) 455-7558 

    (415) 455-7451

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/biomarin-promotes-company-veteran-brian-r-mueller-to-executive-vice-president-cfo-301085332.html

    SOURCE BioMarin Pharmaceutical Inc.

    View Full Article Hide Full Article
  2. SAN RAFAEL, Calif., June 23, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that Henry Fuchs, M.D., President, Worldwide Research & Development and Brian Mueller, Acting Chief Financial Officer, will participate in the BofA Securities 2020 Napa Biopharma Conference on June 24, 2020 at 11:30am ET.  An audio webcast of the presentation will be available live. You can access the webcast at: https://investors.biomarin.com/. An archived version of the remarks will also be available through the Company's website for a limited time following the conference.

    About BioMarin

    BioMarin is a global biotechnology company that develops and commercializes innovative therapies for people with serious and life-threatening rare disorders. The company's portfolio consists of six commercialized products and multiple clinical and pre-clinical product candidates.  

    For additional information, please visit www.biomarin.com. Information on BioMarin's website is not incorporated by reference into this press release.

    Contacts:



    Investors

    Media

    Traci McCarty

    Debra Charlesworth

    BioMarin Pharmaceutical Inc.

    BioMarin Pharmaceutical Inc.

    (415) 455-7558

    (415) 455-7451

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/biomarin-to-participate-in-the-virtual-bofa-securities-2020-napa-biopharma-conference-301080544.html

    SOURCE BioMarin Pharmaceutical Inc.

    View Full Article Hide Full Article
  3. ~ Biopharma Executive Brings 35 Years of Research and Development Leadership ~

    LEXINGTON, Mass. and AMSTERDAM, June 17, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the appointment of Leonard E. Post, Ph.D. to its Board of Directors. Dr. Post, who will also chair the Company's Research & Development Committee, has extensive biotechnology industry experience including previous global R&D leadership roles at BioMarin and Onyx Pharmaceuticals.

    "It is with great pleasure that we nominate Len to the uniQure board," stated Matthew Kapusta, chief executive officer of uniQure.  "His considerable biotechnology experience…

    ~ Biopharma Executive Brings 35 Years of Research and Development Leadership ~

    LEXINGTON, Mass. and AMSTERDAM, June 17, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the appointment of Leonard E. Post, Ph.D. to its Board of Directors. Dr. Post, who will also chair the Company's Research & Development Committee, has extensive biotechnology industry experience including previous global R&D leadership roles at BioMarin and Onyx Pharmaceuticals.

    "It is with great pleasure that we nominate Len to the uniQure board," stated Matthew Kapusta, chief executive officer of uniQure.  "His considerable biotechnology experience, including his important work in gene therapy, are valuable assets for uniQure as we work to advance our pipeline candidates and to prepare to file for marketing authorization of etranacogene dezaparvovec in hemophilia B."

    Since 2016, Dr. Post has served as Chief Scientific Officer of Vivace Therapeutics and its sister company, Virtuoso Therapeutics, both of which are developing oncology therapeutics. From 2010 until 2016, Dr. Post served in various positions at BioMarin (NASDAQ:BMRN), including Chief Scientific Officer, during which time he oversaw the initiation of BioMarin's first gene therapy project for hemophilia A.  Prior to that, Dr. Post served as Chief Scientific Officer of LEAD Therapeutics, Senior Vice President of Research & Development at Onyx Pharmaceuticals and Vice President of Discovery Research at Parke-Davis Pharmaceuticals. He is also currently an advisor to Canaan Partners.

    Dr. Post is a virologist by training and did early work on engineering of herpes simplex virus as a postdoctoral fellow.  He has a Bachelor of Science degree in Chemistry from the University of Michigan, and a Doctorate degree in Biochemistry from the University of Wisconsin. 

    About uniQure

    uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary gene therapies to treat patients with hemophilia B, hemophilia A, Huntington's disease, Fabry disease, spinocerebellar ataxia Type 3 and other diseases. www.uniQure.com

    uniQure Contacts:

    FOR INVESTORS:  FOR MEDIA:
       
    Maria E. CantorChiara E. RussoTom Malone
    Direct: 339-970-7536Direct: 617-306-9137 Direct: 339-970-7558
    Mobile:  617-680-9452Mobile: 617-306-9137Mobile: 339-223-8541
       

    A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/0364d19c-b363-46bb-9277-8e349f7661fd

    Primary Logo

    View Full Article Hide Full Article
  4. SAN RAFAEL, Calif., June 17, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today additional data from its previously reported four-year update of an open-label Phase 1/2 study of valoctocogene roxaparvovec, an investigational gene therapy treatment for severe hemophilia A. The results were presented during a late-breaking oral presentation at the World Federation of Hemophilia (WFH) Virtual Summit by Professor John Pasi, M.B., Ch.B., Ph.D., from Barts and the London School of Medicine and Dentistry and Chief Investigator for this Phase 1/2 study. 

    "With four years of data, this study represents the longest duration of clinical experience for any gene therapy in hemophilia A.  It is exciting to observe that all study participants remain off Factor VIII prophylaxis therapy, while also experiencing a greater than 90 percent reduction in bleeding episodes from a single administration of valoctocogene roxaparvovec," said Professor Pasi.  "These data demonstrate the very real potential of a paradigm shift in the treatment of hemophilia A and that ongoing research into gene therapies could represent an entirely new way to approach meeting the high unmet need in patients with severe hemophilia A."

    "BioMarin is committed to the bleeding disorders community with the most robust and advanced clinical development program for a potential first gene therapy in severe hemophilia A," said Hank Fuchs, M.D., President, Global Research and Development at BioMarin.  "We are pleased to share these data at WFH.  Demonstrating a 96% reduction in exogenous Factor VIII usage as patients are now producing their own endogenous factor VIII is a potential benefit that we hope to be able to offer as we work closely with regulators to seek approval and work to reduce the burden of hemophilia."

    The data presented at WFH is the most current data (April 8, 2020, cut off) and includes four years of data for the 6e13 vg/kg cohort and three years of data for the 4e13 vg/kg cohort. 

    Annualized Bleed Rate and Factor VIII Use in 6e13 vg/kg Cohort

    In the six study participants who were previously on Factor VIII prophylaxis in the 6e13 vg/kg cohort, the data showed substantial and sustained reductions in bleeding that required Factor VIII infusions. In the year prior to treatment with valoctocogene roxaparvovec, the mean Annualized Bleed Rate (ABR) was 16.3 and the median was 16.5. During the four years following treatment with valoctocogene roxaparvovec, the cumulative mean ABR was 0.8, which represents a 95% reduction from baseline. In the fourth year, the mean ABR was 1.3 and the median was zero (see Table 1). There was a 96% reduction in mean Factor VIII usage to 5.4 infusions per year cumulatively over four years from the baseline of 135.6 infusions per year. 

    Among all seven study participants in the 6e13 vg/kg cohort, 86% or six out of seven were bleed-free in the fourth year. All participants remain off Factor VIII prophylaxis therapy (see Table 1).

    Annualized Bleed Rate and Factor VIII Use in 4e13 vg/kg Cohort

    Similarly, in the six study participants in the 4e13 vg/kg cohort, the data showed substantial and sustained reductions in bleeding requiring Factor VIII infusions following treatment with valoctocogene roxaparvovec. All participants remain off Factor VIII prophylaxis therapy. 

    In the year prior to treatment with valoctocogene roxaparvovec, the mean ABR was 12.2 and the median was 8.0. The cumulative mean ABR was reduced by 93% to 0.9 with continued absence of target joint bleeds in 5 of 6 subjects during the three years observed, which represents a 93% reduction from baseline. During the third year of follow-up, the mean ABR was 0.5 and the median was zero (0), and 67% or four out of six study participants were bleed-free. Five out of six participants had no spontaneous bleeds. There was a 96% reduction in mean Factor VIII usage to 5.7 infusions per year cumulatively over three years from the baseline of 142.8 infusions per year. (see Table 1)

    Factor VIII Activity Levels for 6e13 vg/kg and 4e13 vg/kg Cohorts

    For the 6e13 vg/kg and 4e13 vg/kg cohorts, mean Factor VIII activity levels over four and three years, respectively, support the observed reductions in bleed rates and annualized Factor VIII usage. All study participants had severe hemophilia A at baseline, defined as less than or equal to 1 IU/dL of Factor VIII activity.

    At the end of the fourth-year post-infusion with valoctocogene roxaparvovec, all patients continue to produce their own endogenous factor with the mean Factor VIII activity level of the 6e13 vg/kg cohort at 24.2 IU/dL as measured by the chromogenic substrate (CS) assay and at 35.4 IU/dL as measured by the One-Stage (OS) assay.  The median Factor VIII activity levels at the end of the fourth year was 16.4 IU/dL as measured by the CS assay and 23.4 IU/dL as measured by the OS assay.  These measurements are based on six of the seven participants, as an evaluable sample for the seventh study participant was not available.

    Mean Factor VIII activity levels over three years similarly support the observed reductions in bleed rates and annualized Factor VIII usage for the 4e13 vg/kg cohort.  At the end of the third year post-infusion with valoctocogene roxaparvovec, mean Factor VIII activity level of the 4e13 vg/kg cohort was 9.9 IU/dL as measured by the CS assay and 14.9 IU/dL as measured by the OS assay.  The median Factor VIII activity levels at the end of the third year was 7.9 IU/dL as measured by the CS assay and 12.3 IU/dL as measured by the OS assay (see Tables 2 and 3 for graphics of data results).

    Webinar with BioMarin and Study Investigators, Today at 5:00 PM ET 

    At 5pm ET, BioMarin management will host a webinar with key clinical investigators, Professor John Pasi and Dr. Steve Pipe, to discuss results from the Phase 1/2 Study of valoctocogene roxaparvovec gene therapy for severe hemophilia A presented at the WFH Virtual Summit today.  Interested parties may access a live video webinar that will include audio and slides at:  https://bmrn.zoom.us/j/94005113278

    For access to the audio portion only, please use a dial-in number in your region for the highest quality connection:

    U.S. Dial-in Numbers:  +1 669 900 6833  (Bay Area); +1 253 215 8782 (Washington); +1 346 248 7799 (Houston): +1 929 205 6099 (New York); +1 301 715 8592 (Maryland); +1 312 626 6799 (Chicago)

    International Dial-in Numbers Available at: https://bmrn.zoom.us/u/acdpx0wbxX

    Webinar ID: 940 0511 3278

    Safety Summary

    Overall, the safety profile of valoctocogene roxaparvovec remains consistent with previously reported data with no delayed-onset, treatment-related events.  No participants developed inhibitors to Factor VIII, and no participants withdrew from the study.  No participants have developed thrombotic events.  The most common adverse events associated with valoctocogene roxaparvovec occurred early and included transient infusion-associated reactions and transient, asymptomatic, and mild to moderate rise in the levels of certain proteins and enzymes measured in liver function tests with no long-lasting clinical sequelae.

    Robust Clinical Program

    The global Phase 3 study of valoctocogene roxaparvovec at the 6e13 vg/kg dose (GENEr8-1) evaluates superiority of valoctocogene roxaparvovec to the current standard of care, FVIII prophylactic therapy.  The sample size of the GENEr8-1 study is approximately 130 total participants.  Enrollment is completed and the data from this study is expected in the fourth quarter of 2020 or the first quarter of 2021. 

    BioMarin has five clinical studies underway in its comprehensive gene therapy program for the treatment of severe hemophilia A.  In addition to the global Phase 3 study GENEr8-1, the Company is running a Phase 1/2 Study with the 6E13kg/vg dose of valoctocogene roxaparvovec in approximately 10 participants with pre-existing AAV5 antibodies.  The Company is also running two additional and separate studies, one to study AAV seroprevalence in people with severe hemophilia A and one non-interventional study to determine baseline characteristics in people with hemophilia A.  Participants in the Phase 1/2 dose escalation study will continue to be monitored as part of the global program underway. 

    Regulatory Status

    The Food and Drug Administration (FDA) is reviewing the biologics license application, under Priority Review, for valoctocogene roxaparvovec with a PDUFA action date of August 21, 2020. The FDA also granted valoctocogene roxaparvovec Breakthrough Therapy designation. 

    The European Medicines Agency (EMA) validated the Company's Marketing Authorization Application (MAA) for valoctocogene roxaparvovec, which has been in review under accelerated assessment since January.  Recognizing valoctocogene roxaparvovec for its potential to benefit patients with unmet medical needs, EMA granted access to its Priority Medicines (PRIME) regulatory initiative.  Although the MAA remains under accelerated assessment at this time, the Company expects the review procedure to be extended by at least three months due to COVID-19 delays.  Further, the Company believes there is a high possibility that the MAA will revert to the standard review procedure, as is the case with most filings that initially receive accelerated assessment.  Because of the combination of these events, the Company expects an opinion from the Committee for Medicinal Products for Human Use (CHMP) in late 2020/early 2021.

    BioMarin's valoctocogene roxaparvovec has also received orphan drug designation from the FDA and EMA for the treatment of severe hemophilia A. The Orphan Drug Designation program is intended to advance the evaluation and development of products that demonstrate promise for the diagnosis and/or treatment of rare diseases or conditions. 

    The Company believes that both submissions represent the first time a gene therapy product for any type of hemophilia indication is under review for marketing authorization by health authorities.

    About Hemophilia A

    People living with hemophilia A lack sufficient functioning Factor VIII protein to help their blood clot and are at risk for painful and/or potentially life-threatening bleeds from even modest injuries.  Additionally, people with the most severe form of hemophilia A (FVIII levels <1%) often experience painful, spontaneous bleeds into their muscles or joints.  Individuals with the most severe form of hemophilia A make up approximately 50 percent of the hemophilia A population.  People with hemophilia A with moderate (FVIII 1-5%) or mild (FVIII 5-40%) disease show a much-reduced propensity to bleed.  The standard of care for individuals with severe hemophilia A is a prophylactic regimen of replacement Factor VIII infusions administered intravenously up to two to three times per week or 100 to 150 infusions per year.  Despite these regimens, many people continue to experience breakthrough bleeds, resulting in progressive and debilitating joint damage, which can have a major impact on their quality of life. 

    Hemophilia A, also called Factor VIII deficiency or classic hemophilia, is an X-linked genetic disorder caused by missing or defective Factor VIII, a clotting protein. Although it is passed down from parents to children, about 1/3 of cases are caused by a spontaneous mutation, a new mutation that was not inherited. Approximately 1 in 10,000 people have Hemophilia A. 

    About BioMarin

    BioMarin is a global biotechnology company that develops and commercializes innovative therapies for serious and life-threatening rare and ultra-rare genetic diseases. The Company's portfolio consists of six commercialized products and multiple clinical and pre-clinical product candidates. For additional information, please visit www.biomarin.com. Information on BioMarin's website is not incorporated by reference into this press release.

    Forward Looking Statements

    This press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including without limitation, statements about: (i) the development of BioMarin's valoctocogene roxaparvovec program generally, (ii) the impact of valoctocogene roxaparvovec gene therapy for treating patients with severe hemophilia A, (iii) the 4-year data demonstrating the very real potential of a paradigm shift in the treatment of hemophilia A and that ongoing research into gene therapies could represent an entirely new way to approach meeting the high unmet need in patients with severe hemophilia A, (iv) the data from the Company's Phase 3 study expected in the fourth quarter of 2020 or the first quarter of 2021, (v) that Factor VIII activity levels over four years supporting reductions in bleed rates and Factor VIII usage, and (vi) the potential approval and commercialization of valoctocogene roxaparvovec for the treatment of severe hemophilia A, including timing of such approval decisions. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: results and timing of current and planned preclinical studies and clinical trials of valoctocogene roxaparvovec, including final analysis of the above interim data; any potential adverse events observed in the continuing monitoring of the patients in the Phase 1/2 trial; the content and timing of decisions by the FDA, the European Commission and other regulatory authorities, including the potential impact of the COVID-19 pandemic on the regulatory authorities' abilities to issue such decisions and the timing of such decisions; the content and timing of decisions by local and central ethics committees regarding the clinical trials; BioMarin's ability to successfully manufacture valoctocogene roxaparvovec; and those other risks detailed from time to time under the caption "Risk Factors" and elsewhere in BioMarin's Securities and Exchange Commission (SEC) filings, including BioMarin's Quarterly Report on Form 10-Q for the quarter ended March 31, 2020, and future filings and reports by BioMarin. BioMarin undertakes no duty or obligation to update any forward-looking statements contained in this press release as a result of new information, future events or changes in its expectations.

    BioMarin® is a registered trademark of BioMarin Pharmaceutical Inc.

    Contacts:



    Investors

    Media

    Traci McCarty

    Debra Charlesworth

    BioMarin Pharmaceutical Inc.

    BioMarin Pharmaceutical Inc.

    (415) 455-7558 

    (415) 455-7451

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/biomarin-provides-additional-data-from-recent-4-year-update-of-ongoing-phase-12-study-of-valoctocogene-roxaparvovec-gene-therapy-for-severe-hemophilia-a-in-late-breaking-oral-presentation-at-world-federation-of-hemophilia-virtual-301078398.html

    SOURCE BioMarin Pharmaceutical Inc.

    View Full Article Hide Full Article
  5. SAN RAFAEL, Calif., June 3, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer; Henry Fuchs, M.D., President, Worldwide Research & Development; and Brian Mueller, Acting Chief Financial Officer, will participate in the Jefferies Virtual Healthcare Conference on June 4, 2020 at 4:00pm ET and the Goldman Sachs 41st Annual Global Healthcare Conference on June 9, 2020 at 2:10pm ET.  An audio webcast of the presentation will be available live. You can access the webcast at: https://investors.biomarin.com/. An archived version of the remarks will also be available through the Company's website for a limited time following the conference.

    SAN RAFAEL, Calif., June 3, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer; Henry Fuchs, M.D., President, Worldwide Research & Development; and Brian Mueller, Acting Chief Financial Officer, will participate in the Jefferies Virtual Healthcare Conference on June 4, 2020 at 4:00pm ET and the Goldman Sachs 41st Annual Global Healthcare Conference on June 9, 2020 at 2:10pm ET.  An audio webcast of the presentation will be available live. You can access the webcast at: https://investors.biomarin.com/. An archived version of the remarks will also be available through the Company's website for a limited time following the conference.

    About BioMarin

    BioMarin is a global biotechnology company that develops and commercializes innovative therapies for people with serious and life-threatening rare disorders. The company's portfolio consists of six commercialized products and multiple clinical and pre-clinical product candidates.  

    For additional information, please visit www.biomarin.com. Information on BioMarin's website is not incorporated by reference into this press release.

    Contacts:


    Investors

    Media

    Traci McCarty

    Debra Charlesworth

    BioMarin Pharmaceutical Inc.

    BioMarin Pharmaceutical Inc.

    (415) 455-7558

    (415) 455-7451

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/biomarin-to-participate-in-two-upcoming-virtual-investor-conferences-301069809.html

    SOURCE BioMarin Pharmaceutical Inc.

    View Full Article Hide Full Article
View All BioMarin Pharmaceutical Inc. News